Long-term survival in patients with IDH-wildtype glioblastoma: clinical and molecular characteristics-Reference-Cited by-同舟云学术

Long-term survival in patients with IDH-wildtype glioblastoma: clinical and molecular characteristics

Published:2023-03-15 Issue:4 Volume:165 Page:1075-1085
ISSN:0942-0940
Container-title:Acta Neurochirurgica
language:en
Short-container-title:Acta Neurochir

Author:

Chehade Georges,Lawson Tévi Morel,Lelotte Julie,Daoud Lina,Di Perri Dario,Whenham Nicolas,Duprez Thierry,Tajeddine Nicolas,Tissir Fadel,Raftopoulos Christian^ORCID

Funder

Fonds De La Recherche Scientifique - FNRS

Fondation JED

Fondation Médicale Reine Elisabeth

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Surgery

Link

https://link.springer.com/content/pdf/10.1007/s00701-023-05544-3.pdf

Reference40 articles.

1. Adeberg S, Bostel T, Konig L, Welzel T, Debus J, Combs SE (2014) A comparison of long-term survivors and short-term survivors with glioblastoma, subventricular zone involvement: a predictive factor for survival? Radiat Oncol 9:95. https://doi.org/10.1186/1748-717X-9-95

2. Amelot A, De Cremoux P, Quillien V, Polivka M, Adle-Biassette H, Lehmann-Che J, Francoise L, Carpentier AF, George B, Mandonnet E, Froelich S (2015) IDH-mutation is a weak predictor of long-term survival in glioblastoma patients. PLoS One 10:e0130596. https://doi.org/10.1371/journal.pone.0130596

3. Armocida D, Pesce A, Di Giammarco F, Frati A, Santoro A, Salvati M (2019) Long term survival in patients suffering from glio-blastoma multiforme: a single-center observational cohort study. Diagnostics (Basel) 9. https://doi.org/10.3390/diagnostics9040209

4. Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C, Dietrich PY, Weller M, Mariani L, Heppner FL, McDonald DR, Lacombe D, Stupp R, Delorenzi M, Hegi ME (2012) MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol 124:547–560. https://doi.org/10.1007/s00401-012-1016-2

5. Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, Shonka N, Gilbert MR, Sawaya R, Prabhu SS, Weinberg J, Lang FF, Aldape KD, Sulman EP, Rao G, McCutcheon IE, Cahill DP (2014) IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 16:81–91. https://doi.org/10.1093/neuonc/not159

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advancements in understanding of biological role of homeobox C9 in human cancers;World Journal of Clinical Oncology;2024-09-24

2. Validating a clinically based MS-MLPA threshold through comparison with Sanger sequencing in glioblastoma patients;2024-09-08

3. Genomics and proteomics to determine novel molecular subtypes and predict the response to immunotherapy and the effect of bevacizumab in glioblastoma;Scientific Reports;2024-07-31

4. Comprehensive molecular characterization of long-term glioblastoma survivors;Cancer Letters;2024-07

5. DIAPH3 predicts survival of patients with MGMT-methylated glioblastoma;Frontiers in Oncology;2024-02-22